Patient-reported outcomes with nivolumab plus cabozantinib in advanced kidney cancer

Ongoing results from the phase 3 CheckMate-9ER clinical trial with nivolumab plus cabozantinib have been published in The Lancet Oncology this week. Previous trial results have shown that the nivolumab/cabozantinib combination doubled the average time to when the treatment stopped working and the cancer started growing again (progression-free survival) compared to sunitinib and nearly twice as many previously untreated renal cell carcinoma (RCC) patients responded […]

read more

Atezolizumab plus bevacizumab does not improve survival in kidney cancer

Results from the IMmotion151 phase III clinical trial were published in JAMA Oncology this week and showed that a combination of atezolizumab and bevacizumab did not improve overall survival time compared with sunitinib in patients with previously untreated, metastatic renal cell carcinoma (RCC). The researchers said they “do not have a clear explanation” for these […]

read more

European Commission approves pembrolizumab plus lenvatinib as first-line treatment for advanced kidney cancer

The European Commission has approved the combination of pembrolizumab, an anti-PD-1 immunotherapy, plus lenvatinib, an oral tyrosine kinase inhibitor, for the first-line treatment of people with advanced renal cell carcinoma (RCC) for use within the European Union (including Northern Ireland). The approval is based on the results from the phase 3 CLEAR/KEYNOTE-581 trial, in which […]

read more

First-line nivolumab plus ipilimumab in kidney cancer patients without nephrectomy

A recent post hoc analysis of the CheckMate 214 trial looked at the nivolumab plus ipilimumab combination in 108 patients with advanced renal cell carcinoma (RCC) who had not had surgery to remove their cancer (nephrectomy). Patients were randomised to nivolumab plus ipilimumab every 3 weeks followed by nivolumab alone (53 patients) or sunitinib every […]

read more

Immunotherapy combinations in the first-line treatment of metastatic sarcomatoid kidney cancer

A recent study looked at the efficacy and safety of first-line treatment with a combination of immunotherapies (immune checkpoint inhibitors) for sarcomatoid renal cell carcinoma (RCC). The analysis included five clinical trials involving 568 patients with sarcomatoid RCC. All combinations that were looked at significantly improved progression-free survival and response rate. Combination treatments with nivolumab […]

read more

Real world incidence of immune-related side effects to ipilimumab/nivolumab in kidney cancer patients

A recent study published in Journal of Clinical Medicine this month reports the real-world incidence of immune-related side effects associated with nivolumab plus ipilimumab in patients with renal cell carcinoma (RCC). This observational study looked at the incidence and severity of immune-related side effects in 41 patients taking nivolumab plus ipilimumab for the treatment of […]

read more

Efficacy and safety of gemcitabine plus doxorubicin in patients with renal medullary carcinoma

Renal medullary carcinoma (RMC) is an extremely rare and aggressive form of kidney cancer. It is almost exclusively found in young people who carry the sickle cell gene. The sickle cell gene is particularly common in people with an African or Caribbean family background and can cause a group of inherited conditions that affect the red blood […]

read more

SMC approves cabozantinib/nivolumab combination for advanced kidney cancer in Scotland

The Scottish Medicines Consortium (SMC) has approved the use of the combination of cabozantinib (a vascular endothelial growth factor (VEGF) inhibitor) plus nivolumab (an immunotherapy) for use by NHS Scotland for the treatment of untreated people with advanced renal cell carcinoma (RCC). The approval was based on the results from a phase 3 study, which […]

read more

Cabozanitinib in combination with atezolizumab for advanced kidney cancer

This phase Ib study reports the results of a combination of cabozantinib plus atezolizumab in people with advanced clear cell and non–clear cell renal cell carcinoma (RCC). The number and nature of side effects to the 40 mg and 60 mg dose of cabozantinib were similar. Around two thirds of patients reported side effects to […]

read more

Outcomes and side effects after first-line treatment with combination therapies for kidney cancer

This report looked at the results from 4 studies comparing sunitinib with various immunotherapy combinations: nivolumab/ipilimumab, pembrolizumab/axitinib, nivolumab/cabozantinib and pembrolizumab/lenvatinib. Overall survival time, time to when the cancer started growing again and the treatment stopped working (progression-free survival), response to treatment in terms of the cancer getting smaller, and side effects to treatment were all […]

read more
Showing 1 to 10 of 159 results
  TOP